FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF
[EN] FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF<br/>[FR] INHIBITEURS DE FXA AVEC L'AMIDOXIME CYCLIQUE OU L'AMIDRAZONE CYCLIQUE EN TANT QUE SOUS-UNITÉ P4, PROCÉDÉS POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES ET DÉRIVÉS DE CEUX-CI
申请人:LEGOCHEM BIOSCIENCE LTD
公开号:WO2010002115A3
公开(公告)日:2010-03-11
EP2307407B1
申请人:——
公开号:EP2307407B1
公开(公告)日:2016-03-16
US8178525B2
申请人:——
公开号:US8178525B2
公开(公告)日:2012-05-15
FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF
申请人:Song Ho Young
公开号:US20110112083A1
公开(公告)日:2011-05-12
The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.